Olaparib (AstraZeneca)will not proceed to Phase III in Ovarian Cancer

AstraZenenca announced that Olaparib will not progress into Phase III development for the maintenance treatment of serious Ovarian Cancer. The decision to discontinue olaparib�s development in Ovarian Cancer was made following a review of an interim analysis of a Phase II study (study 19) which indicated that the previously reported progression free survival benefit is unlikely to translate into an overall survival benefit, the definitive measure of patient benefit in Ovarian Cancer. In addition, attempts to identify a suitable tablet dose for use in Phase III studies have not been successful.